^
    1year
    B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Tongji University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Aug 2022 --> Aug 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    B010-A
    over2years
    B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=3, Recruiting, Tongji University | Trial primary completion date: May 2022 --> Aug 2022
    Trial primary completion date
    |
    GPC3 (Glypican 3) • CRP (C-reactive protein)
    |
    GPC3 positive
    |
    B010-A
    almost3years
    B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=3, Recruiting, Tongji University | Initiation date: Jul 2021 --> Oct 2021
    Trial initiation date
    |
    GPC3 (Glypican 3) • CRP (C-reactive protein)
    |
    GPC3 positive
    |
    B010-A
    3years
    B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=3, Recruiting, Tongji University
    Clinical • New P1 trial
    |
    GPC3 (Glypican 3) • CRP (C-reactive protein)
    |
    GPC3 positive
    |
    B010-A